On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


ChineseInvestors.com, Inc. (CIIX) – A First Mover in CBD Skin Care

  • China is the second-largest global cosmetics consumer, representing $30 billion annually
  • Savvy industry veteran recruited for vast untapped CBD skin care market
  • 100% of cannabis skin care product market in China up for grabs

It comes as little surprise that cannabidiol (CBD) likely possesses skin healing properties. Found in the marijuana plant, CBD is one of over 80 natural compounds in marijuana that have been used for centuries as natural medicines and therapeutics. Cannabis is a known anti-inflammatory, containing antioxidants and anti-aging elements, while hemp seed oil contains both omega-3 and omega-6 fatty acids.

In spite of vast anecdotal evidence, science has not yet definitively settled on the positive effects of CBD skin care. However, the recent article “The Role of Cannabinoids in Dermatology,” published in the prestigious Journal of American Academy of Dermatology, suggests efficacy in CBD use for the treatment of several dermatologic conditions, including pruritus, inflammatory skin disease and skin cancer (http://dtn.fm/tQ6BS). It’s likely that even more beneficial effects will be found.

Further scientific validation will be icing on the cake for ChineseInvestors.com, Inc. (OTCQB: CIIX). With the introduction of its line of cannabidiol-based skin care products, CIIX is primed and fast moving into the multi-billion dollar Chinese skin care industry. The company has already filed a record of its first line of hemp-infused skin care products with the China Food and Drug Administration and expects to launch it in the next couple months. As the company stated in a recent press release, “Although ancient Chinese recognized the medicinal properties of the cannabis plant, CBD extract appears to be largely unrecognized in China today for its benefits, including but not limited to, its potential benefits to the largest visible human organ, the skin.”

China is the second-largest consumer of skin care products in the world and generates nearly $30 billion in annual retail sales. Since no other notable manufacturers have entered the cannabis skin care product market in China, CIIX would be first to market and anticipates capturing “100% of China’s market share in this novel skin care products category.” The market potential is immense.

To facilitate and expedite market dominance, CIIX recently appointed skin care industry veteran and Shanghai beauty influencer Fannie (Chun Fang) Tang as marketing director of its wholly-owned CBD Biotechnology Co., Ltd. enterprise. Well known in China, Tang will be responsible for developing and implementing branding strategies for the company’s CBD Magic Hemp Series skin care line (http://dtn.fm/ilH21).

Tang has proven success in the industry, bringing more than two decades of industry experience and previously serving as the CEO of L.D. Waxson, a leading skin care company with a footprint throughout China and much of Southeast Asia. Moving from CEO to director of marketing is a strong testament to the opportunity. There’s little doubt that with Tang’s experience, guidance and industry connections, CBD Biotechnology will position itself to become a leader in China’s skin care industry.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

From Our Blog

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

March 28, 2024

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year. “In 2023 […]

Rotate your device 90° to view site.